CRS conducts In-house Phase I Clinical Trials within its dedicated early-phase clinical research unit, providing sponsors with full control, close medical oversight, and integrated operational execution. Our facility is specifically designed to support first-in-human and complex early-phase studies in a controlled and compliant clinical environment.

We specialize in the conduct of FIH, SAD, MAD, food-effect, bioavailability, bioequivalence, and other early-phase designs in healthy volunteers and selected patient populations. Studies are performed under continuous medical supervision with immediate access to trained investigators, nursing staff, and emergency support. This structure enables rapid response to safety findings and efficient execution of protocol-driven activities.

CRS manages all aspects of In-house Phase I trial conduct, including subject recruitment, screening, dosing, inpatient and outpatient visits, pharmacokinetic sampling, and safety monitoring. Our unit is equipped to handle intensive PK schedules, overnight confinement, and complex dosing regimens, ensuring accurate data collection and protocol compliance.

Clinical operations are fully integrated with pharmacovigilance, regulatory affairs, data management, and project management functions. This allows seamless coordination of safety reporting, dose escalation decisions, and study amendments, while maintaining full regulatory compliance and data integrity.

By combining dedicated infrastructure, experienced early-phase staff, and integrated CRO services, CRS delivers Phase I clinical trials that prioritize subject safety, operational reliability, and high-quality clinical data to support confident development decisions.